What is HC Wainwright's Estimate for GALT Q2 Earnings?

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings estimates for Galectin Therapeutics in a report issued on Tuesday, June 17th. HC Wainwright analyst M. Keller expects that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($0.72) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05.

Galectin Therapeutics Stock Performance

Shares of GALT stock opened at $3.29 on Thursday. Galectin Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $3.30. The stock has a 50 day simple moving average of $1.39 and a two-hundred day simple moving average of $1.44. The company has a market cap of $208.22 million, a P/E ratio of -4.57 and a beta of 0.54.

Institutional Trading of Galectin Therapeutics

Several large investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. lifted its position in shares of Galectin Therapeutics by 8.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company's stock valued at $516,000 after acquiring an additional 34,300 shares during the period. HighTower Advisors LLC increased its stake in Galectin Therapeutics by 244.1% in the first quarter. HighTower Advisors LLC now owns 77,375 shares of the company's stock valued at $94,000 after purchasing an additional 54,889 shares in the last quarter. Nuveen LLC acquired a new position in shares of Galectin Therapeutics during the first quarter valued at about $34,000. Y Intercept Hong Kong Ltd bought a new position in shares of Galectin Therapeutics during the 1st quarter worth about $287,000. Finally, Sovran Advisors LLC boosted its position in shares of Galectin Therapeutics by 7.4% during the 1st quarter. Sovran Advisors LLC now owns 199,830 shares of the company's stock worth $244,000 after purchasing an additional 13,816 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company's stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.